BNP PARIBAS ASSET MANAGEMENT Holding S.A. Reduces Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 907,044 shares of the biopharmaceutical company’s stock after selling 4,131 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 1.59% of Agios Pharmaceuticals worth $40,300,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AGIO. Farallon Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the period. Marshall Wace LLP grew its stake in shares of Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after buying an additional 348,808 shares during the period. Finally, Candriam S.C.A. acquired a new position in Agios Pharmaceuticals in the second quarter valued at approximately $13,922,000.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AGIO shares. Raymond James reissued an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $52.33.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $55.54 on Friday. The firm has a market capitalization of $3.17 billion, a PE ratio of 4.89 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The firm’s 50-day moving average is $47.24 and its two-hundred day moving average is $44.36.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.